Skip to content

Study · Measured the body's own peptide · 2010

9 results

Actin-sequestering protein, thymosin beta-4, is a novel hypoxia responsive regulator.

Moon EY, Im YS, Ryu YK, Kang JH

Clinical & experimental metastasis7 Sept 2010Cited by 20 (Europe PMC)

PMID20821256 (opens in a new tab)DOI10.1007/s10585-010-9350-z (opens in a new tab)PepBankPUB-20821256
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01LabEndogenous levelIn vitro (cells)Mechanism

    In B16F10 melanoma cells, the cells' own thymosin beta‑4 expression increased with hypoxia conditioning in a time-dependent manner.

    In plain wordsIn cells, hypoxia raised the cells' own thymosin beta‑4 level over time.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseTB4 expression under hypoxia
    Study

    mousen: not reported in source

    B16F10 melanoma cells
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    TB4 expression in B16F10 cells was increased by hypoxia conditioning in a time-dependent manner.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

Studies that did not test the peptide alone8

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 02AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome

    TB4-transgenic mice showed more angiogenesis than wildtype mice.

    In plain wordsIn mice bred to make extra thymosin beta‑4, blood vessel growth was higher than in normal mice.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseAngiogenesis in TB4-transgenic mice
    Study

    mousen: not reported in source

    TB4-transgenic mice
    Comparator
    Wildtype mice
    Outcome group
    Angiogenesis · Cancer

    Source sentences

    Summary
    we found an increase of angiogenesis and HIF-1α expression in TB4-transgenic (Tg) mice as compared to wildtype mice.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 03AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Mechanism

    TB4-transgenic mice showed higher HIF-1alpha expression than wildtype mice.

    In plain wordsIn mice bred to make extra thymosin beta‑4, HIF-1alpha was higher than in normal mice.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseHIF-1alpha expression in TB4-transgenic mice
    Study

    mousen: not reported in source

    TB4-transgenic mice
    Comparator
    Wildtype mice
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    we found an increase of angiogenesis and HIF-1α expression in TB4-transgenic (Tg) mice as compared to wildtype mice.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  3. 04AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome

    TB4-transgenic mice showed more tumor growth than wildtype mice.

    In plain wordsIn mice bred to make extra thymosin beta‑4, tumors grew more than in normal mice.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseTumor growth in TB4-transgenic mice
    Study

    mousen: not reported in source

    TB4-transgenic mice
    Comparator
    Wildtype mice
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    We also found an increase of tumor growth and lung metastasis count in TB4-Tg mice as compared to wildtype mice.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  4. 05AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome

    TB4-transgenic mice showed a higher lung metastasis count than wildtype mice.

    In plain wordsIn mice bred to make extra thymosin beta‑4, more tumor spread to the lungs occurred than in normal mice.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseLung metastasis count in TB4-transgenic mice
    Study

    mousen: not reported in source

    TB4-transgenic mice
    Comparator
    Wildtype mice
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    We also found an increase of tumor growth and lung metastasis count in TB4-Tg mice as compared to wildtype mice.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  5. 06LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Efficacy outcome

    In B16F10 melanoma cells, lentiviral shRNA knockdown of TB4 expression retarded tumor cell migration.

    In plain wordsIn cells, blocking the cells' own thymosin beta‑4 made tumor cells move more slowly.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseTumor cell migration after TB4 knockdown
    Study

    mousen: not reported in source

    B16F10 melanoma cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    When TB4 expression in B16F10 cells was inhibited by the infection with small hairpin (sh) RNA of TB4 cloned in lentiviral vector, tumor cell migration was retarded.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  6. 07LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Efficacy outcome

    In B16F10 melanoma cells, lentiviral shRNA of TB4 reduced hypoxia conditioning-induced tumor cell migration.

    In plain wordsIn cells, blocking the cells' own thymosin beta‑4 reduced the extra cell movement caused by low oxygen.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseHypoxia-induced tumor cell migration after TB4 knockdown
    Study

    mousen: not reported in source

    B16F10 melanoma cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    In addition, hypoxia conditioning-induced tumor cell migration was reduced by the infection of lentiviral shRNA of TB4.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  7. 08LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism

    In B16F10 melanoma cells, lentiviral shRNA of TB4 reduced HIF-1alpha stabilization in hypoxia.

    In plain wordsIn cells, blocking the cells' own thymosin beta‑4 reduced HIF-1alpha stabilization in low oxygen.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseHIF-1alpha stabilization in hypoxia after TB4 knockdown
    Study

    mousen: not reported in source

    B16F10 melanoma cells
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    HIF-1α stabilization and the expression of VEGF isoform 165 and 121 in hypoxia were also reduced by the infection of lentiviral shRNA of TB4 in B16F10 cells.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  8. 09LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism

    In B16F10 melanoma cells, lentiviral shRNA of TB4 reduced the expression of VEGF isoforms 165 and 121 in hypoxia.

    In plain wordsIn cells, blocking the cells' own thymosin beta‑4 reduced two VEGF forms in low oxygen.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseVEGF isoform 165 and 121 expression in hypoxia after TB4 knockdown
    Study

    mousen: not reported in source

    B16F10 melanoma cells
    Outcome group
    Angiogenesis · Cancer

    Source sentences

    Summary
    HIF-1α stabilization and the expression of VEGF isoform 165 and 121 in hypoxia were also reduced by the infection of lentiviral shRNA of TB4 in B16F10 cells.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.